Radiotherapy

Radiotherapy or radiation therapy is the general term for the use of radiation in the treatment of disease. Radiotherapy uses ionizing radiation to kill harmful cells in the body. Ionizing radiation can come from many sources, such as x-rays, gamma rays, or proton beams.

When used for cancer treatments, radiation kills cancerous cells and shrinks tumors. Radiation therapy can be used in combination with other treatments, such as chemotherapy, hormone therapy, or surgery, or it can be used alone in the treatment of the disease. The treatment approach relies on the type of cancer and the stage of the disease.

Radiation for Lymphomas

Radiation therapy has been used successfully in the treatment of lymphomas for many years. Lymph cells are incredibly sensitive to radiation, which is why this treatment is so effective. To treat lymphomas, doctors will expose a patient to radiation from an outside source, usually a machine. This external-beam radiation therapy will target cancerous cells wherever it is applied.

Radioimmunotherapy (radiolabeled monoclonal antibodies)

Radioimmunotherapy combines radiotherapy with monoclonal antibody therapy. Though it was developed in the 1980's, radioimmunotherapy is just now beginning to gain widespread acceptance. In the United States, it has been approved by the FDA for treatment of certain refractory and relapse NHL's. Zevalin® has been approved by the FDA as a first-line radioummunotherapy treatment for certain types of follicular lymphomas.

Your Radiation Team

When a patient undergoes radiation therapy, s/he has a team of knowledgeable and experienced doctors. This group consists of a radiation oncologist, a radiation physicist, a dosimetrist, and a radiation therapy nurse.

The radiation oncologist reviews a patient's medical records, scans, blood tests, and any other pertinent information. They conduct a physical exam on the patient as well. Based on their examinations, the radiation oncologist will estimate what areas of the body need radiotherapy. These areas are called the treatment fields or ports. In lymphomas, the treatment fields are usually in the neck, torso, and groin, where the highest concentrations of lymph nodes are.

To accurately determine treatment fields, the radiation oncologist may have a lymphoma patient perform a simulation. During a radiotherapy simulation, the oncologist uses low-dose x-rays to examine the patient's internal organs and narrow their estimated treatment fields. These simulations can take an hour or two, so the patient may need to be sedated to prevent unwanted movement.

Once the radiation oncologist has determined the patient's treatment fields, they will consult with the radiation physicist and dosimetrist to determine the dose of radiation. Together, these three professionals pick a dose appropriate for the type of lymphoma and the stage of the disease. This dose is then divided up over the treatment period, which can last for several weeks.

As with chemotherapy, radiation therapy can cause significant side effects.

More Articles about Radiotherapy

Resources

Photo from NCI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap